We showed that the MLL-r leukemia cells with acquired resistance to the compound underwent genetic and phenotypic changes (increased sensitivity to glycolysis inhibitors, increased HIF1α levels) corresponding to reprogramming toward a more glycolytic metabolic profile compared to the parental cells from which they were derived. The gene discussed is HIF1A; the disease is leukemia.